Beyond AREDS Formulations, What Is Next for Intermediate Age-Related Macular Degeneration (iAMD) Treatment? Potential Benefits of Antioxidant and Anti-inflammatory Apocarotenoids as Neuroprotectors

Age-related macular degeneration (AMD) is the commonest cause of severe visual loss and blindness in developed countries among individuals aged 60 and older. AMD slowly progresses from early AMD to intermediate AMD (iAMD) and ultimately late-stage AMD. Late AMD encompasses either neovascular AMD (nA...

Descripción completa

Detalles Bibliográficos
Autores principales: Camelo, Serge, Latil, Mathilde, Veillet, Stanislas, Dilda, Pierre J., Lafont, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803142/
https://www.ncbi.nlm.nih.gov/pubmed/33520083
http://dx.doi.org/10.1155/2020/4984927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803142/
https://www.ncbi.nlm.nih.gov/pubmed/33520083
http://dx.doi.org/10.1155/2020/4984927

Ejemplares similares